Tumor–associated antigens identified by mRNA expression profiling as tumor rejection epitopes
AUTOR(ES)
Andersen, Marie Louise
FONTE
BioMed Central
RESUMO
Thirteen H-2b-binding peptides derived from six potentially overexpressed proteins in p53-/- thymoma (SM7) cells were studied for immunogenecity and vaccine-induced prevention of tumor growth in mice inoculated with SM7 tumor cells. Six of the peptides generated specific CTL responses after immunization, but only two of these peptides (RAD23–31 and RAD24–31) were capable of generating a weak vaccination-induced protection against adoptive tumor growth. SM7 inoculated mice treated with a blocking antibody against the inhibitory T cell signal transducing molecule CTLA4 appeared to delay tumor take, suggesting that SM7 thymoma cells are recognized by the adaptive immune system of the host. However, prophylactic vaccination with RAD23–31 and RAD24–31 peptides combined with anti-CTLA4 Ab treatment and did not improve tumor resistance. Our data would indicate that vaccination with immunogenic peptides derived from potentially overexpressed tumor proteins, as identified by mRNA expression profiling of p53-/- thymoma cells, at best results in a weak tumor protection thus questioning this way of detection of new tumor rejection epitopes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=153425Documentos Relacionados
- Tumor-associated transplantation antigens in immune rejection of mouse malignant cell hybrids.
- Purification of Hodgkin's Disease Tumor-Associated Antigens
- Tumor-associated mutations of rat mitochondrial transfer RNA genes.
- Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens.
- Cloning and expression of the tumor-associated antigen L6.